Search

Search Constraints

You searched for: Author/Creator Yano, Seiji

Search Results

1. A phase I/II study of osimertinib in EGFR exon 20 insertion mutation-positive non-small cell lung cancer. (December 2021)

2. Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib‐resistance of EML4‐ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors. Issue 1 (30th December 2016)

3. Androgen replacement therapy for cancer‐related symptoms in male: result of prospective randomized trial (ARTFORM study). Issue 4 (24th May 2021)

4. Bronchoesophageal fistula formation after three courses of nivolumab for carcinoma of unknown primary with a subgroup of lung squamous cell carcinoma. Issue 12 (28th December 2020)

5. Cancer among children, adolescents and young adults in the Hokushin region, Japan, between 2010 and 2015. (16th November 2021)

9. Heterogeneity among tumors with acquired resistance to EGFR tyrosine kinase inhibitors harboring EGFR‐T790M mutation in non‐small cell lung cancer cells. (14th January 2022)

10. High levels of AXL expression in untreated EGFR‐mutated non‐small cell lung cancer negatively impacts the use of osimertinib. Issue 2 (11th November 2022)